Home > Stocks > Commentaries
Drug Roundup: September 18, 2014
There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve. Companies mentioned in this review include Pfizer Inc. (PFE), AstraZeneca (AZN), Merck & Co. (MRK), AbbVie Inc. (ABBV), and Eli Lilly (LLY) Read more
The Dogs Lost Some Steam In The August Heat, But Maintained Their Lead
As the U.S. bull market for equities marches toward a sixth straight year, major benchmarks such as the S&P 500 and Dow Jones Industrials have clawed their ways to new highs. However, the numbers alone don’t tell the whole story. The Dogs of the Dow strategy, unsurprisingly, is also benefitting from the upswing, advancing every month with the exception of January. Although August found the pack lagging the gains posted by the 30 Dow Industrials as a whole, year-to-date performance has maintained a relatively comfortable lead. Merck and Microsoft logged the biggest gains last month, but Intel’s stock has outrun the Dogs (and the rest of the Dow components, for that matter) by a sizable margin so far this year. Read more
Restaurant Roundup: September 11, 2014
The end of the third quarter is rapidly approaching, so we will preview the upcoming earnings season for the restaurant industry. We will also take a look at a large proposed acquisition, the impact of rising wages and food costs, and a recent supplier issue. Read more
GMO Update: Is Organic Gaining Ground?
As the anti-GMO (genetically modified organisms) movement begins to rack up some victories, organic foods are enjoying greater popularity. Read more
Technology Round Up: September 4, 2014
There have been many noteworthy developments in the technology space recently. Some of these will likely have a material impact on the companies in the sector and the markets they serve. Companies featured here include Amazon.com (AMZN), Google (GOOG), Alibaba, Apple (AAPL), Samsung, and Compuware (CPWR). Read more
The OCC And The National Banking System
The Office of the Comptroller of the Currency, or OCC, has played a key role in the creation of the national banking system and in restoring the industry’s health during times of financial crisis. It continues to monitor the condition of the banking sector, and provides investors with a wealth of information regarding the industry. Read more
Retail Roundup: August 28, 2014
Earnings season has come and gone and the results were fairly clear: Most retailers continue to deal with the ill effects of a still-sluggish economic environment. Although there were a few that persevered and were able to post better-than-expected results, the majority operating in this space continued to struggle on a year-over-year basis. Read more
Federal Reserve Nearly Halfway To Completing Its Policy Transition
The Federal Reserve is close to ending its massive bond buying program. The next step is to normalize interest rates. But what is normal? Read more
Drug Roundup: August 21, 2014
There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve. Companies mentioned in this review include Pfizer Inc. (PFE), Merck & Co. (MRK), Valeant Pharmaceuticals International Inc. (VRX), and Allergan Inc. (AGN). Read more
Cloud-Based EHRs: Fad or Future
Cloud-based electronic health records have emerged as a popular choice among practitioners. Should investors get behind this technology or is this merely the latest fleeting craze? Read more
[First] [Previous] [Next] [last]
Loading...
Free stock reports
The Value Line 600
Value Line is regarded as the best independent research available. More than just recommendations, Value Line provides the rationale behind its picks for greater understanding.
- Don D., California